Login / Signup

Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.

Andrés Muñoz MartinLaura Ortega MoránAna GutiérrezEnrique GallardoDarío Rubio-RodríguezCarlos Rubio-TerrésBlanca MorónPilar García AlfonsoJosé Manuel Soria
Published in: Journal of medical economics (2023)
In thromboprophylaxis of cancer patients, the use of apixaban and rivaroxaban generated similar cost compared to non-prophylaxis, without the difference found being statistically significant, with a clinically insignificant QALY gain.
Keyphrases
  • venous thromboembolism
  • direct oral anticoagulants
  • papillary thyroid
  • atrial fibrillation
  • squamous cell
  • locally advanced
  • squamous cell carcinoma
  • lymph node metastasis